Canada markets open in 9 hours 11 minutes

HUTCHMED (China) Limited (HCM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.41-0.23 (-1.69%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close13.64
Open13.64
Bid13.20 x 1300
Ask14.16 x 800
Day's Range13.16 - 13.74
52 Week Range7.39 - 21.28
Volume150,333
Avg. Volume254,291
Market Cap2.363B
Beta (5Y Monthly)0.89
PE Ratio (TTM)N/A
EPS (TTM)-2.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.91
  • GlobeNewswire

    HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further to its announcement on January 23, 2023 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502, NYSE:TAK) to further the global development, commercialization and manufac

  • GlobeNewswire

    HUTCHMED Confirms No Assets Held at Silicon Valley Bank

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today confirms that it does not have any exposure to Silicon Valley Bank (“SVB”) or Silicon Valley Bank UK Limited (“SVBUK”). The Company does not hold any cash deposits or securities with SVB or SVBUK. About HUTCHMED HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is comm

  • GlobeNewswire

    HUTCHMED Reports 2022 Full Year Results and Provides Business Updates

    Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full Year 2022 oncology/immunology revenues driven by significant increase in China in-market sales of ELUNATE®, SULANDA® and ORPATHYS® alongside clinical and strategic progress Company to Host Annual Results Call & Webcast Today at 9 p.m. HKT / 1 p.m. GMT / 8 a.m. EST HONG KONG, SHANGHAI, China and FLORHAM P